Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?

被引:0
作者
Christophe Le Terrier
Samanta Freire
Patrice Nordmann
Laurent Poirel
机构
[1] University of Fribourg,Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine
[2] University hospitals of Geneva,Division of Intensive Care Unit
[3] Swiss National Reference Center for Emerging Antibiotic Resistance,undefined
来源
European Journal of Clinical Microbiology & Infectious Diseases | 2024年 / 43卷
关键词
Cefiderocol; Taniborbactam; Avibactam; Nacubactam; Zidebactam; Relebactam; Vaborbactam; β-Lactamase;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:339 / 354
页数:15
相关论文
共 180 条
[1]  
Nordmann P(2019)Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria Clin Infect Dis 69 S521-S528
[2]  
Poirel L(2006)Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Antimicrob Agents Chemother 50 1633-1641
[3]  
Quale J(2009) clinical isolates Antimicrob Agents Chemother 53 4783-4788
[4]  
Bratu S(2003)Molecular epidemiology and mechanisms of carbapenem resistance in Microbiol Mol Biol Rev 67 593-656
[5]  
Gupta J(2017)Molecular basis of bacterial outer membrane permeability revisited Clin Microbiol Rev 30 1-22
[6]  
Landman D(2022)Carbapenem-resistant Clin Infect Dis 75 187-212
[7]  
Rodríguez-Martínez JM(2022) and Enterobacteriaceae in South and Southeast Asia Antimicrob Agents Chemother 66 e0003922-680
[8]  
Poirel L(2021)Infectious Diseases Society of America 2022 Guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) Antimicrob Agents Chemother 65 e0087721-66
[9]  
Nordmann P(2022)Impact of acquired broad-spectrum β-lactamases on susceptibility to cefiderocol and newly developed β-lactam/β-lactamase inhibitor combinations in Eur J Clin Microbiol Infect Dis 41 677-S650
[10]  
Nikaido H(2023) and Int J Antimicrob Agents 62 106917-e00120